Latest News - Tarix Orphan LLC

Monday, June 12, 2017 | Product Launches and Updates, Research and Publications, Tarix Orphan LLC

EMA Grants Orphan Status to Tarix’s EB Candidiate

The European Medicines Agency (EMA) granted Orphan Drug status to Tarix Orphan LLC’s lead compound, TXA127, for the treatment of epidermolysis bullosa (EB). TXA127 is a pharmaceutical gr…

Read the full story